Cited by 2,207Cancer Genomics and DiagnosticsBRCA gene mutations in cancerBreast Cancer Treatment Studies

The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.

Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer

Open access

Dawson, Sarah-Jane, Tsui, Dana W.Y., Murtaza, Muhammed, Biggs, Heather, Rueda, Oscar M., Chin, Suet-Feung, Dunning, Mark J., Gale, Davina, Forshew, Tim, Mahler-Araujo, Betania, Rajan, Sabrina, Humphray, Sean, Becq, Jennifer, Halsall, David, Wallis, Matthew, Bentley, David, Caldas, Carlos, Rosenfeld, Nitzan·2013·New England Journal of Medicine

DOI 10.1056/nejmoa1213261

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The management of metastatic breast cancer requires monitoring of the tumor burden to determine the response to treatment, and improved biomarkers are needed. Biomarkers such as cancer antigen 15-3 (CA 15-3) and circulating tumor cells have been widely studied. However, circulating cell-free DNA carrying tumor-specific alterations (circulating tumor DNA) has not been extensively investigated or compared with other circulating biomarkers in breast cancer. METHODS: We compared the radiographic imaging of tumors with the assay of circulating tumor DNA, CA 15-3, and circulating tumor cells in 30 women with metastatic breast cancer who were receiving systemic therapy. We used targeted or whole-genome sequencing to identify somatic genomic alterations and designed personalized assays to quantify circulating tumor DNA in serially collected plasma specimens. CA 15-3 levels and numbers of circulating tumor cells were measured at identical time points. RESULTS: Circulating tumor DNA was successfully detected in 29 of the 30 women (97%) in whom somatic genomic alterations were identified; CA 15-3 and circulating tumor cells were detected in 21 of 27 women (78%) and 26 of 30 women (87%), respectively. Circulating tumor DNA levels showed a greater dynamic range, and greater correlation with changes in tumor burden, than did CA 15-3 or circulating tumor cells. Among the measures tested, circulating tumor DNA provided the earliest measure of treatment response in 10 of 19 women (53%). CONCLUSIONS: This proof-of-concept analysis showed that circulating tumor DNA is an informative, inherently specific, and highly sensitive biomarker of metastatic breast cancer. (Funded by Cancer Research UK and others.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1213261

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1994) · doi:10.1201/9780429246593 · Cited by 40,500
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,468
An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1993) · doi:10.1007/978-1-4899-4541-9 · Cited by 21,230
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Self-citation
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,602
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Isolation of rare circulating tumour cells in cancer patients by microchip technology
Nagrath, S., Sequist, L. V. D., Maheswaran, S., Bell, D. W., Irimia, D., Ulkus, L., Smith, M. R., Kwak, E. L., Digumarthy, S. R., Muzikansky, A., et al. (2007) · Nature · doi:10.1038/nature06385 · Cited by 3,595
Cell-free nucleic acids as biomarkers in cancer patients
Schwarzenbach, H., Hoon, D. S. �., & Pantel, K. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3066 · Cited by 2,897

Show all 44 references

Research works printed but not linked: 2

Lauro S, 1999, Anticancer Res, 19, 3511
Chen X, 1999, Clin Cancer Res, 5, 2297

Sorted by citations

Items 501–600 of 1,003

Brain Tumor Imaging
Brindle, K. M., Izquierdo-García, J. L., Lewis, D. Y., Mair, R. J., & Wright, A. J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.7636 · Cited by 70
Identifying non-muscle-invasive and muscle-invasive bladder cancer based on blood serum surface-enhanced Raman spectroscopy
Chen, S., Zhu, S., Cui, X., Xu, W., Kong, C., Zhang, Z., & Qian, W. (2019) · Biomedical Optics Express · doi:10.1364/boe.10.003533 · Cited by 70
Molecular Residual Disease and Adjuvant Trial Design in Solid Tumors
Coakley, M. F., García-Murillas, I., & Turner, N. C. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0152 · Cited by 69
A novel nest hybridization chain reaction based electrochemical assay for sensitive detection of circulating tumor DNA
Huang, Y., Tao, M., Luo, S., Zhang, Y., Situ, B., Ye, X., Chen, P., Jiang, X., Wang, Q., & Zheng, L. (2020) · Analytica Chimica Acta · doi:10.1016/j.aca.2020.02.006 · Cited by 68
Non‐invasive detection of genome‐wide somatic copy number alterations by liquid biopsies
Heitzer, E., Ulz, P., Geigl, J. B., & Speicher, M. R. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.12.004 · Cited by 71
Results of the first external quality assessment scheme (EQA) for isolation and analysis of circulating tumour DNA (ctDNA)
Haselmann, V., Ahmad‐Nejad, P., Geilenkeuser, W. J., Duda, A., Gabor, M., Eichner, R., Patton, S. J., & Neumaier, M. (2017) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2017-0283 · Cited by 69
Review of the clinical applications and technological advances of circulating tumor DNA in cancer monitoring
Chang, Y., Tolani, B., Nie, X., Zhi, X., Hu, M., & He, B. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s141991 · Cited by 73
Correlation between circulating cell‐free PIK 3 CA tumor DNA levels and treatment response in patients with PIK 3 CA ‐mutated metastatic breast cancer
Kodahl, A. R., Ehmsen, S., Pallisgaard, N., Jylling, A. M. B., Jensen, J. D., Lænkholm, A., Knoop, A. S., & Ditzel, H. J. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12305 · Cited by 72
Urinary Exosomal and cell-free DNA Detects Somatic Mutation and Copy Number Alteration in Urothelial Carcinoma of Bladder
Lee, D. H., Yoon, H., Park, S., Kim, J. S., Ahn, Y., Kwon, K., Lee, D., & Kim, K. H. (2018) · Scientific Reports · doi:10.1038/s41598-018-32900-6 · Cited by 69
Next-Generation Liquid Biopsies: Embracing Data Science in Oncology
Im, Y. R., Tsui, D. W. Y., Diaz, L. A., & Wan, J. C. M. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.11.001 · Cited by 68
Self-citation
Anti-HER2 therapy in metastatic breast cancer: many choices and future directions
Wynn, C., & Tang, S. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10021-x · Cited by 75
Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acids
Imamura, T., Komatsu, S., Ichikawa, D., Kawaguchi, T., Miyamae, M., Okajima, W., Ohashi, T., Arita, T., Konishi, H., Shiozaki, A., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i25.5627 · Cited by 73
Cell-free circulating tumor DNA analysis for breast cancer and its clinical utilization as a biomarker
Wang, R., Li, X., Zhang, H., Wang, K., & He, J. (2017) · Oncotarget · doi:10.18632/oncotarget.20608 · Cited by 70
Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy
Ahronian, L. G., & Corcoran, R. B. (2017) · Genome Medicine · doi:10.1186/s13073-017-0431-3 · Cited by 67
Precision Medicine in Low- and Middle-Income Countries
Radich, J. P., Briercheck, E. L., Chiu, D. T., Menon, M. P., Torra, O. S., Yeung, C. C. S., & Warren, E. H. (2022) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-042320-034052 · Cited by 67
Circulating Methylated XAF1 DNA Indicates Poor Prognosis for Gastric Cancer
Ling, Z., Lv, P., Lu, X., Yu, J.-L., Han, J., Ying, L., Zhu, X., Zhu, W., Fang, X., Wang, S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067195 · Cited by 67
Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib
Wong, A. L. A., Lim, J. S. J., Sinha, A. K., Gopinathan, A., Lim, R. S. C., Tan, C., Soh, I., Venkatesh, S. K., Titin, C., Sapari, N. S., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0405-4 · Cited by 68
The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation
Carpinetti, P. A., Donnard, E. R., Bettoni, F., Asprino, P. F., Koyama, F. C., Rozanski, A., Sabbaga, J., Habr‐Gama, A., Parmigiani, R. B., Galante, P. A. F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5256 · Cited by 67
Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion
Wang, H., Stoecklein, N. H., Lin, P. P., & Gires, O. (2016) · Oncotarget · doi:10.18632/oncotarget.12242 · Cited by 69
How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case
Appierto, V., Cosimo, S. D., Reduzzi, C., Pala, V., Cappelletti, V., & Daidone, M. G. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.04.007 · Cited by 69
Parallel Analyses of Somatic Mutations in Plasma Circulating Tumor DNA (ctDNA) and Matched Tumor Tissues in Early-Stage Breast Cancer
Zhang, X., Zhao, W., Wei, W., You, Z., Ou, X., Sun, M., Yin, Y., Tang, X., Zhao, Z., Hu, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4055 · Cited by 68
The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape
Vanni, I., Tanda, E. T., Spagnolo, F., Andreotti, V., Bruno, W., & Ghiorzo, P. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00113 · Cited by 69
Genome Sequencing during a Patient’s Journey through Cancer
Nangalia, J., & Campbell, P. J. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1910138 · Cited by 66
Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study
Sueoka‐Aragane, N., Katakami, N., Satouchi, M., Yokota, S., Aoe, K., Iwanaga, K., Otsuka, K., Morita, S., Kimura, S. H., Negoro, S., et al. (2015) · Cancer Science · doi:10.1111/cas.12847 · Cited by 67
Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA
Gao, M., Callari, M., Beddowes, E. J., Sammut, S., Grzelak, M., Biggs, H., Jones, L. R., Boumertit, A., Linn, S. C., Cortés, J., et al. (2019) · Genome Medicine · doi:10.1186/s13073-018-0611-9 · Cited by 66
Self-citation
Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review)
Finotti, A., Allegretti, M., Gasparello, J., Giacomini, P., Spandidos, D. A., Spoto, G., & Gambari, R. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4516 · Cited by 66
Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib
Oh, C. R., Kong, S., Im, H.-S., Kim, H. J., Kim, M. K., Yoon, K., Cho, E., Jang, J.-H., Lee, J., Kang, J., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5483-x · Cited by 66
Landscape of circulating tumour DNA in metastatic breast cancer
Davis, A. A., Jacob, S. L., Gerratana, L., Shah, A. N., Wehbe, F., Katam, N., Zhang, Q., Flaum, L., Siziopikou, K. P., Platanias, L. C., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102914 · Cited by 69
Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens
Takeshita, T., Yamamoto, Y., Yamamoto‐Ibusuki, M., Inao, T., Sueta, A., Fujiwara, S., Omoto, Y., & Iwase, H. (2015) · Translational research · doi:10.1016/j.trsl.2015.09.003 · Cited by 68
Quantification of Somatic Chromosomal Rearrangements in Circulating Cell-Free DNA from Ovarian Cancers
Harris, F. R., Kovtun, I. V., Smadbeck, J. B., Multinu, F., Jatoi, A., Kosari, F., Kalli, K. R., Murphy, S. J., Halling, G. C., Johnson, S. H., et al. (2016) · Scientific Reports · doi:10.1038/srep29831 · Cited by 66
Very Short Mitochondrial DNA Fragments and Heteroplasmy in Human Plasma
Zhang, R., Nakahira, K., Guo, X., Choi, A. M. K., & Gu, Z. (2016) · Scientific Reports · doi:10.1038/srep36097 · Cited by 66
Methylation patterns in serum DNA for early identification of disseminated breast cancer
Widschwendter, M., Evans, I., Jones, A., Ghazali, S., Reisel, D., Ryan, A., Gentry‐Maharaj, A., Zikán, M., Cibula, D., Eichner, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0499-9 · Cited by 70
Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer.
Bordi, P., Re, M. D., Danesi, R., & Tiseo, M. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.08.09 · Cited by 66
A second space age spanning omics, platforms and medicine across orbits
Mason, C. E., Green, J., Adamopoulos, K. I., Afshin, E. E., Baechle, J. J., Basner, M., Bailey, S. M., Bielski, L., Borg, J., Borg, J., et al. (2024) · Nature · doi:10.1038/s41586-024-07586-8 · Cited by 68
Liquid biopsy of gastric cancer patients: Circulating tumor cells and cell-free nucleic acids
Tsujiura, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i12.3265 · Cited by 65
Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy
Haselmann, V., Gebhardt, C., Brechtel, I., Duda, A., Czerwinski, C., Sucker, A., Holland‐Letz, T., Utikal, J. S., Schadendorf, D., & Neumaier, M. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2017.281543 · Cited by 65
The Use of Microfluidic Technology for Cancer Applications and Liquid Biopsy
Kulasinghe, A., Wu, H., Punyadeera, C., & Warkiani, M. E. (2018) · Micromachines · doi:10.3390/mi9080397 · Cited by 67
Quantitative Identification of Mutant Alleles Derived from Lung Cancer in Plasma Cell-Free DNA via Anomaly Detection Using Deep Sequencing Data
Kukita, Y., Uchida, J., Oba, S., Nishino, K., Kumagai, T., Taniguchi, K., Okuyama, T., Imamura, F., & Kato, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081468 · Cited by 64
Bioinformatics Analysis for Circulating Cell-Free DNA in Cancer
Huang, C., Du, M., & Wang, L. (2019) · Cancers · doi:10.3390/cancers11060805 · Cited by 67
Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors
Heidrich, I., Deitert, B., Werner, S., & Pantel, K. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10075-x · Cited by 65
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Tokudome, N., & Hayes, D. F. (2013) · Breast Diseases A Year Book Quarterly · doi:10.1016/j.breastdis.2013.10.034 · Cited by 64
Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non‐Small Cell Lung Cancer
Jia, Q., Chiu, L.-T., Wu, S., Bai, J., Peng, L., Zheng, L., Zang, R., Li, X., Yuan, B., Gao, Y., et al. (2020) · Advanced Science · doi:10.1002/advs.201903410 · Cited by 64
Prognostic role of PIK 3 CA mutations of cell‐free DNA in early‐stage triple negative breast cancer
Takeshita, T., Yamamoto, Y., Yamamoto‐Ibusuki, M., Inao, T., Sueta, A., Fujiwara, S., Omoto, Y., & Iwase, H. (2015) · Cancer Science · doi:10.1111/cas.12813 · Cited by 64
Quantitative ultrasound assessment of breast tumor response to chemotherapy using a multi-parameter approach
Tadayyon, H., Sannachi, L., Gangeh, M. J., Naini, A. S., Tran, W. T., Trudeau, M., Pritchard, K. I., Ghandi, S., Verma, S., & Czarnota, G. J. (2016) · Oncotarget · doi:10.18632/oncotarget.8862 · Cited by 63
Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer
Cheng, J., Holland‐Letz, T., Wallwiener, M., Surowy, H., Ćuk, K., Schott, S., Trumpp, A., Pantel, K., Sohn, C., Schneeweiß, A., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4666-5 · Cited by 65
The Role of Circulating Free DNA and MicroRNA in Non-Invasive Diagnosis of HBV- and HCV-Related Hepatocellular Carcinoma
Pezzuto, F., Buonaguro, L., Buonaguro, F. M., & Tornesello, M. L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041007 · Cited by 63
Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients
Darrigues, L., Pierga, J., Bernard‐Tessier, A., Bièche, I., Silveira, A. B., Michel, M., Loirat, D., Cottu, P. H., Cabel, L., Dubot, C., et al. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01411-0 · Cited by 63
TNscope: Accurate Detection of Somatic Mutations with Haplotype-based Variant Candidate Detection and Machine Learning FilteringPreprint
Freed, D. N., Pan, R., & Aldana, R. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/250647 · Cited by 60
The landscape of cell-free mitochondrial DNA in liquid biopsy for cancer detection
van der Pol, Y., Moldován, N., Ramaker, J., Bootsma, S., Lenos, K., Vermeulen, L., Sandhu, S. K., Bahce, I., Pegtel, D. M., Wong, S. Q., et al. (2023) · Genome biology · doi:10.1186/s13059-023-03074-w · Cited by 62
Self-citation
Personalized medicine: Present and future of breast cancer management
Sabatier, R., Gonçalvès, A., & Bertucci, F. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.03.002 · Cited by 65
Technical Validation of a Next-Generation Sequencing Assay for Detecting Clinically Relevant Levels of Breast Cancer–Related Single-Nucleotide Variants and Copy Number Variants Using Simulated Cell-Free DNA
Yang, X., Chu, Y., Zhang, R., Han, Y., Zhang, L., Fu, Y., Li, D., Peng, R., Li, D., Ding, J., et al. (2017) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2017.04.007 · Cited by 62
Fully automated, on-site isolation of cfDNA from whole blood for cancer therapy monitoring
Kim, C., Park, J., Sunkara, V., Kim, T.-H., Lee, Y., Lee, K., Kim, M., & Cho, Y. (2018) · Lab on a Chip · doi:10.1039/c8lc00165k · Cited by 62
Cell‐Free Virus‐Host Chimera DNA From Hepatitis B Virus Integration Sites as a Circulating Biomarker of Hepatocellular Cancer
Li, C., Ho, M., Lin, Y., Tzeng, S., Chen, Y., Pai, H., Wang, Y.-C., Chen, C., Lee, Y., Chen, D., et al. (2020) · Hepatology · doi:10.1002/hep.31230 · Cited by 67
Liquid biopsy: An emerging prognostic and predictive tool in Head and Neck Squamous Cell Carcinoma (HNSCC). Focus on Circulating Tumor Cells (CTCs)
Economopoulou, P., Kotsantis, I., Kyrodimos, E., Lianidou, E. S., & Psyrri, A. K. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.09.012 · Cited by 64
Evaluation and consequences of heterogeneity in the circulating tumor cell compartment
Brouwer, A., Laere, B. D., Peeters, D. J. E., Peeters, M., Salgado, R., Dirix, L. Y., & Laere, S. V. (2016) · Oncotarget · doi:10.18632/oncotarget.8015 · Cited by 64
Methylated free‐circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancer
Herbst, A., Vdovin, N., Gacesa, S., Philipp, A. B., Nagel, D., Holdt, L. M., den Winkel, M. O., Heinemann, V., Stieber, P., Graeven, U., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30625 · Cited by 62
Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer
Allin, D., Shaikh, R., Carter, P., Thway, K., Sharabiani, M. T. A., de Castro, D. G., O’Leary, B., García-Murillas, I., Bhide, S. A., Hubank, M. J. F., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.08.013 · Cited by 62
BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease
Jankú, F., Vibat, C. R. T., Kosco, K. A., Holley, V. R., Cabrilo, G., Meric‐Bernstam, F., Stepanek, V. M. T., Lin, P. P., Leppin, L., Hassaine, L., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1964 · Cited by 62
Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients
Takeshita, T., Yamamoto, Y., Yamamoto‐Ibusuki, M., Inao, T., Sueta, A., Fujiwara, S., Omoto, Y., & Iwase, H. (2016) · Oncotarget · doi:10.18632/oncotarget.8839 · Cited by 60
Liquid biopsy in pancreatic cancer: the beginning of a new era
Yadav, D. K., Bai, X., Yadav, R. K., Singh, A., Li, G., Ma, T., Chen, W., & Liang, T. (2018) · Oncotarget · doi:10.18632/oncotarget.24809 · Cited by 62
Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma
Wierzbicki, K., Ravi, K., Franson, A. T., Bruzek, A. K., Cantor, E., Harris, M. K., Homan, M. J., Marini, B. L., Kawakibi, A. R., Ravindran, R., et al. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0877-0 · Cited by 62
Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy
Boonstra, P. A., Wind, T. T., van Kruchten, M., Schuuring, E. M. D., Hospers, G. A. P., van der Wekken, A. J., de Groot, D. J. A., Schröder, C. P., Fehrmann, R. S. N., & Reyners, A. K. L. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09876-9 · Cited by 60
Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA
Bos, M. K., Nasserinejad, K., Jansen, M. P. H. M., Steendam, C. M. J., Angus, L., Atmodimedjo, P. N., de Jonge, E., Dinjens, W. N. M., van Schaik, R. H. N., Re, M. D., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12827 · Cited by 60
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests
Wan, J. C. M., Sasieni, P. D., & Rosenfeld, N. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01033-x · Cited by 69
Self-citation
Personalized Ovarian Cancer Disease Surveillance and Detection of Candidate Therapeutic Drug Target in Circulating Tumor DNA
Martignetti, J. A., Camacho‐Vanegas, O., Priedigkeit, N., Camacho, C., Pereira, E. B., Li, L., Garnar-Wortzel, L., Miller, D., Losic, B., Shah, H., et al. (2014) · Neoplasia · doi:10.1593/neo.131900 · Cited by 62
The translational potential of circulating tumour DNA in oncology
Patel, K., & Tsui, D. W. Y. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2015.04.005 · Cited by 64
Self-citation
New challenges in perioperative management of pancreatic cancer
Puleo, F. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i8.2281 · Cited by 60
Design and Analysis for Studying microRNAs in Human Disease: A Primer on -Omic Technologies
Nair, V. S., Pritchard, C. C., Tewari, M., & Ioannidis, J. P. A. (2014) · American Journal of Epidemiology · doi:10.1093/aje/kwu135 · Cited by 62
Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients
Liang, D. H., Ensor, J., Liu, Z.-B., Patel, A., Patel, T. A., Chang, J. C., & Rodriguez, A. A. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3635-5 · Cited by 61
Reversibly Stabilized Polycation Nanoparticles for Combination Treatment of Early- and Late-Stage Metastatic Breast Cancer
Chen, G., Wang, Y., Wu, P., Zhou, Y., Yu, F., Zhu, C., Li, Z., Yu, H., Wang, K., Li, J., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b01482 · Cited by 59
Liquid Biopsies in Head and Neck Cancer: Current State and Future Challenges
Kong, L., & Birkeland, A. C. (2021) · Cancers · doi:10.3390/cancers13081874 · Cited by 60
Current and Developing Liquid Biopsy Techniques for Breast Cancer
Wu, H., & Chu, P. (2022) · Cancers · doi:10.3390/cancers14092052 · Cited by 66
Far Beyond the Usual Biomarkers in Breast Cancer: A Review
Pultz, B. D. A., da Luz, F. A. C., de Faria, P. R., Oliveira, A. P. L., de Araújo, R. A., & Silva, M. J. B. (2014) · Journal of Cancer · doi:10.7150/jca.8925 · Cited by 61
Clinical Relevance of Alterations in Quantity and Quality of Plasma DNA in Colorectal Cancer Patients: Based on the Mutation Spectra Detected in Primary Tumors
Lin, J.-K., Lin, P.-C., Lin, C., Jiang, J., Yang, S.-H., Liang, W.-Y., Chen, W.-S., & Chang, S. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3804-5 · Cited by 59
Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients
Winther‐Larsen, A., Demuth, C., Fledelius, J., Madsen, A. T., Hjorthaug, K., Meldgaard, P., & Sørensen, B. S. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.215 · Cited by 59
Prognostic potential of liquid biopsy tracking in the posttreatment surveillance of patients with nonmetastatic nasopharyngeal carcinoma
Chen, F., Huang, X., Lv, J., Wen, D., Zhou, G., Lin, L. C., Kou, J., Wu, C., Chen, Y., Zheng, Z., et al. (2020) · Cancer · doi:10.1002/cncr.32770 · Cited by 59
Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer
Walter, V. P., Fischer, C., Deutsch, T. M., Ersing, C., Nees, J., Schütz, F., Fremd, C., Grischke, E., Sinn, H., Brucker, S. Y., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05746-8 · Cited by 62
Liquid biopsy in ovarian cancer: Catching the silent killer before it strikes
Feeney, L., Harley, I. J. G., McCluggage, W. G., Mullan, P. B., & Beirne, J. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i11.868 · Cited by 62
Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR
Palacín-Aliana, I., Garcia‐Romero, N., Asensi-Puig, A., Carrión-Navarro, J., González‐Rumayor, V., & Ayuso‐Sacido, Á. (2021) · Biomedicines · doi:10.3390/biomedicines9080906 · Cited by 63
Assessment of DNA Integrity, Applications for Cancer Research
Zonta, E., Nizard, P., & Taly, V. (2015) · Advances in clinical chemistry · doi:10.1016/bs.acc.2015.03.002 · Cited by 60
Practicing Pathology in the Era of Big Data and Personalized Medicine
Gu, J., & Taylor, C. R. (2013) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000022 · Cited by 58
Genetic heterogeneity in breast cancer: the road to personalized medicine?
Baird, R. D., & Caldas, C. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-151 · Cited by 59
Self-citation
Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients
Riediger, A. L., Dietz, S., Schirmer, U. B., Meister, M. A., Heinzmann-Groth, I., Schneider, M. A., Muley, T., Thomas, M., & Sültmann, H. (2016) · Scientific Reports · doi:10.1038/srep33505 · Cited by 59
Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden
Maia, M. C., Bergerot, P. G., Dizman, N., Hsu, J., Jones, J. O., Lanman, R. B., Banks, K. C., & Pal, S. K. (2017) · Kidney Cancer · doi:10.3233/kca-170007 · Cited by 57
Tumor DNA: an emerging biomarker in head and neck cancer
Bellairs, J. A., Hasina, R., & Agrawal, N. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9685-x · Cited by 60
Salivary Exosome and Cell-Free DNA for Cancer Detection
Hyun, K.-A., Gwak, H., Lee, J., Kwak, B., & Jung, H. (2018) · Micromachines · doi:10.3390/mi9070340 · Cited by 58
Detection of TP53 and PIK3CA Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis
Rodríguez, B. J., Córdoba, G. D., Aranda, A. G., Álvarez, M., Vicioso, L., Pérez, C. L., Hernándo, C., Bermejo, B., Julve, A., Lluch, A. M., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081183 · Cited by 60
ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials
Noé, J., Lovejoy, A., Ou, S. I., Yaung, S. J., Bordogna, W., Klass, D. M., Cummings, C. A., & Shaw, A. T. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.10.015 · Cited by 56
Targeted deep sequencing revealed variants in cell-free DNA of hormone receptor-positive metastatic breast cancer patients
Keup, C., Benyaa, K., Hauch, S., Sprenger‐Haussels, M., Tewes, M., Mach, P., Bittner, A., Kimmig, R., Hahn, P. F., & Kasimir‐Bauer, S. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03189-z · Cited by 59
Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer
Paracchini, L., Beltrame, L., Grassi, T., Inglesi, A., Fruscio, R., Landoni, F., Ippolito, D., Marchette, M. D., Paderno, M., Adorni, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3345 · Cited by 57
Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy
Ortolan, E., Appierto, V., Silvestri, M., Miceli, R., Veneroni, S., Folli, S., Pruneri, G., Vingiani, A., Belfiore, A., Cappelletti, V., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100086 · Cited by 57
Liquid biopsy: Comprehensive overview of circulating tumor DNA (Review)
Ge, Q., Zhang, Z., Li, S.-N., Ma, J., & Zhao, Z. (2024) · Oncology Letters · doi:10.3892/ol.2024.14681 · Cited by 57
Progress in the application of molecular biomarkers in gliomas
Wang, J., Su, H.-K., Zhao, H., Chen, Z.-P., & To, S. S. T. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.07.148 · Cited by 59
Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review
Syn, N. L. X., Yong, W. P., Goh, B. C., & Lee, S. C. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1196187 · Cited by 59
Monitoring multiple myeloma by quantification of recurrent mutations in serum
Rustad, E. H., Coward, E., Skytøen, E. R., Misund, K., Holien, T., Standal, T., Børset, M., Beisvåg, V., Myklebost, O., Meza‐Zepeda, L. A., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.160564 · Cited by 58
The challenges of modeling hormone receptor-positive breast cancer in mice
Özdemir, B. C., Sflomos, G., & Brisken, C. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0063 · Cited by 57
Autoantibodies as Potential Biomarkers in Breast Cancer
Qiu, J., Keyser, B., Lin, Z., & Wu, T. (2018) · Biosensors · doi:10.3390/bios8030067 · Cited by 56
A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer
Chen, X., Qiu, T., Zhu, Y., Sun, J., Li, P., Wang, B., Lin, P., Cai, X., Han, X., Zhao, F., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0164 · Cited by 57
Cell‐free DNA profiling in retinoblastoma patients with advanced intraocular disease: An MSKCC experience
Kothari, P. D., Marass, F., Yang, J. L., Stewart, C. M., Stephens, D. P., Patel, J., Hasan, M., Jing, X., Meng, F., Enriquez, J., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3144 · Cited by 59
Self-citation
Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale
Barber, L. J., Davies, M. N., & Gerlinger, M. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2014.12.001 · Cited by 57

Authors: Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., Dunning, M. J., Gale, D., Forshew, T., Mahler-Araujo, B., Rajan, S., Humphray, S., Becq, J., Halsall, D., Wallis, M., Bentley, D., Caldas, C., & Rosenfeld, N.
Affiliations: University of Cambridge (GB)
National Health Service (GB)
ORCID: Dawson, Sarah-Jane
Tsui, Dana W.Y.
Murtaza, Muhammed
Biggs, Heather
Rueda, Oscar M.
Chin, Suet-Feung
Dunning, Mark J.
Gale, Davina
Forshew, Tim
Mahler-Araujo, Betania
Humphray, Sean
Halsall, David
Wallis, Matthew
Caldas, Carlos
Rosenfeld, Nitzan
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2013-03-28
Volume: 368
Issue: 13
Pages: 1199-1209
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1213261
OpenAlex: W2140575188
Cited by: 2,207
References: 44
Citations by year: 2026: 86 · 2025: 96 · 2024: 106 · 2023: 109 · 2022: 169 · 2021: 180 · 2020: 197 · 2019: 220 · 2018: 197 · 2017: 224 · 2016: 204 · 2015: 195 · 2014: 135 · 2013: 82
FWCI: 72.15
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
Funders: Cancer Research UK (11906, 16942, 22310)
National Institute for Health and Care Research (NF-SI-0611-10154)
NIHR Cambridge Biomedical Research Centre
Cancer Research UK Cambridge Institute, University of Cambridge
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: circulating tumor DNA, metastatic breast cancer, liquid biopsy, CA15-3, circulating tumor cells, treatment response monitoring, tumor burden, somatic alterations, circulating biomarkers, early detection of treatment response
MeSH terms: Breast Neoplasms, DNA, Neoplasm, Female, Humans, Mutation, Neoplasm Metastasis, Prognosis, Radiography, Sensitivity and Specificity, Biomarkers, Tumor, Sequence Analysis, DNA, Mucin-1, Tumor Burden, Genome-Wide Association Study

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks